BTG (LON:BTG) was upgraded by Shore Capital to a “buy” rating in a report released on Monday.
BTG has been the topic of a number of other research reports. Numis Securities reiterated a “buy” rating and set a GBX 900 ($12.43) price objective on shares of BTG in a research note on Friday, December 8th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of BTG in a research note on Monday, January 15th. Finally, Peel Hunt reiterated a “hold” rating and set a GBX 700 ($9.67) price objective on shares of BTG in a research note on Thursday, February 1st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. BTG currently has a consensus rating of “Buy” and a consensus price target of GBX 774.13 ($10.70).
BTG (BTG) traded up GBX 0.50 ($0.01) during midday trading on Monday, hitting GBX 659.50 ($9.11). 200,827 shares of the company were exchanged, compared to its average volume of 582,586. BTG has a fifty-two week low of GBX 559.82 ($7.73) and a fifty-two week high of GBX 784 ($10.83). The firm has a market capitalization of $2,640.00 and a price-to-earnings ratio of 3,471.05.
TRADEMARK VIOLATION WARNING: “BTG (BTG) Stock Rating Upgraded by Shore Capital” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3302494/btg-btg-stock-rating-upgraded-by-shore-capital.html.
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.